Risk factors for treatment delay in pulmonary tuberculosis in Recife, Brazil

dos Santos, Martinho A. P. S.; Albuquerque, Maria F. P. M.; Ximenes, Ricardo A. A.; Lucena-Silva, Norma L. C. L.; Braga, Cynthia; Campelo, Antônio R. L.; Dantas, Odimariles M. S.; Montarroyos, Ulisses R.; Souza, Wayner V.; Kawasaki, Alexandre M.; Rodrigues, Laura C.
January 2005
BMC Public Health;2005, Vol. 5 Issue 1, p25
Academic Journal
Background: Tuberculosis is still a great challenge to public health in Brazil and worldwide. Early detection followed by effective therapy is extremely important in controlling the disease. Recent studies have investigated reasons for delays in treatment, but there is no agreed definition of what constitutes an "acceptable" delay. This study investigates factors associated with total delay in treatment of tuberculosis. Methods: A cohort of adult cases of pulmonary tuberculosis diagnosed over a two-year period was studied. Patients were interviewed on entry, reporting the duration of symptoms before the start of treatment, and sputum and blood samples were collected. It was decided that sixty days was an acceptable total delay. Associations were investigated using univariable and multivariable analysis and the population attributable fraction was estimated. Results: Of 1105 patients, 62% had a delay of longer than 60 days. Age, sex, alcoholism and difficulty of access were not associated with delays, but associations were found in the case of unemployment, having given up smoking, having lost weight and being treated in two of the six health districts. The proportion attributable to: not being an ex-smoker was 31%; unemployment, 18%; weight loss, 12%, and going to the two worst health districts, 25%. Conclusion: In this urban area, delays seem to be related to unemployment and general attitudes towards health. Although they reflect the way health services are organized, delays are not associated with access to care.


Related Articles

  • Government told to set clearer TB action targets.  // Nursing Standard;2/9/2005, Vol. 19 Issue 22, p6 

    Focuses on specific targets needed to ensure the British government's action plan on tuberculosis (TB). Reason for the limitation of the plan; Scope of the action plan; Importance of controlling the spread of the disease.

  • Tuberculosis of the talus in the child. Teklali, Youssef; Alami, Zouheir Fellous El; Madhi, Tarik El; Gourinda, Hassan; Miri, Adbelhamid // European Journal of Orthopaedic Surgery & Traumatology;Mar2003, Vol. 13 Issue 1, p52 

    Objective. Authors report an exceptional localization of tuberculosis in children. Background. Tuberculosis became a pathology of high incidence in the last 20 years, even in industrialized countries. Localization in the talus is rarely reported (less than 100 pediatric cases worldwide). The...

  • Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis? Hatherill, M.; Hawkridge, T.; Zar, H. J.; Whitelaw, A.; Tameris, M.; Workman, L.; Geiter, L.; Hanekom1, W. A.; Hussey, G. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Mar2009, Vol. 94 Issue 3, p195 

    Objectives: To compare the diagnostic yield of Mycobacterium tuberculosis from induced sputum (IS) and gastric lavage (GL) among children in a community setting. Methods: Specimen-collection methods for bacteriological confirmation of pulmonary tuberculosis (PTB) were compared during a...

  • DNA vaccines against tuberculosis. Lowrie, Douglas B.; Silva, Cello L.; Tascon, Ricardo E. // Immunology & Cell Biology;Dec1997, Vol. 75 Issue 6, p591 

    This edited transcript of a presentation at the 'Vaccines Beyond 2000' conference describes a series of investigations by the authors throwing light on the mechanisms of protective immunity against tuberculosis in mice and raising hope for a new kind of vaccine to replace bacille...

  • Behind The Headlines: Vaccine may offer new hope in TB. Polak, Monika // GP: General Practitioner;11/5/2004, p20 

    The article presents information on a new vaccine that might improve tuberculosis (TB) protection if used with BCG. Reports described how the experimental vaccine MVA85A had passed phase-one safety studies with flying colours. Larger trials are under way in Gambia and are generating very...

  • DNA vaccine for TB prevents recurrence. Bowden, Rachel // GP: General Practitioner;2/11/2005, p4 

    This article informs that a DNA vaccine for TB prevents recurrence of the disease in mice. Researchers infected four groups of mice with a low dose of Mycobacterium tuberculosis and treated them with the anti-tubercular agents isoniazid and pyrazinamide five times in the first four to 16 weeks...

  • Management of Spontaneous Pneumothorax in a Developing Caribbean Nation: A Clinical Practice Audit. Cawich, Shamir O.; Williams, Eric W.; Irvine, Roger; Harding, Hyacinth E.; Isaacs, Melody // Internet Journal of Pulmonary Medicine;2009, Vol. 10 Issue 2, p8 

    A five year clinical audit was conducted between January 1, 2000 and January 1, 2005 to evaluate the management of patients with spontaneous pneumothoraces at three tertiary referral centres across Kingston, the capital city of Jamaica. Secondary pneumothoraces (SSP) were considered present if...

  • Tuberculosis in UK prisoners: a challenge for control. Anderson, Charlotte; Story, Alistair; Brown, Tim; Drobniewski, Francis; Abubakar, Ibrahim // Journal of Epidemiology & Community Health;Apr2010, Vol. 64 Issue 4, p18 

    Aims Prisoners include a disproportionate number of those with social and clinical risk factors for tuberculosis and pose a challenge for control. The aim of this study was to investigate the characteristics of prisoners with tuberculosis in order to inform clinical management and control...

  • Immunological requirements for a subunit vaccine against tuberculosis. Elhay, Martin J.; Andersen, Peter // Immunology & Cell Biology;Dec1997, Vol. 75 Issue 6, p595 

    Tuberculosis remains one of the most important threats to world health. Current vaccination and prevention strategies are inadequate and there is an urgent need for a new vaccine. The current vaccine bacille Calmette-Guerin (BCG). is unable to protect against re-activation of disease in later...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics